Table 1.
Specific hematologic and serum biochemical data in a patient with metastatic gastric cancer and rare severe immune-related cholestatic hepatitis and subsequent severe late-onset pneumonia after pembrolizumab therapy.
| Hospital day |
Total bilirubin (5–21 μmol/L) |
Direct bilirubin (<3.4 μmol/L) |
AST (<50 IU/L) |
ALT (<50 IU/L) |
|---|---|---|---|---|
| 1 | 12.8 | 4.9 | 40 | 43 |
| 11 | 171.4 | 114.3 | 49 | 54 |
| 16 | 139.3 | 88.4 | 38 | 41 |
| 18 | 115.1 | 69.9 | 35 | 35 |
| 21 | 102.5 | 60.5 | 37 | 37 |
| 23 | 101.3 | 57.9 | 46 | 42 |
| 27 | 73.7 | 41.3 | 50 | 43 |
| 30 | 68.7 | 38.7 | 62 | 41 |
| 33 | 55 | 30.7 | 57 | 36 |
| 46 | 43.5 | 21.5 | 42 | 49 |
| 49 | 29.5 | 15.5 | 36 | 33 |
| 90 | 26.2 | 15.7 | 38 | 48 |
AST, aspartate aminotransferase; ALT, alanine aminotransferase. The bold values indicates the peak level of total bilirubin and direct bilirubin in this patient.